

DAFTAR PUSTAKA

1. Adiyanti SS, Suryaatmadja M. 2016. Peran Galectin-3 sebagai Petanda Fibrosis Jantung. Dalam: Sukartini N, Timan IS. Timan (Editor), Pendidikan Berkesinambungan Patologi Klinik 2016. Jakarta: Departemen Patologi Klinik Fakultas Kedokteran Universitas Indonesia.
2. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, et al. 2011. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. *Annals of Medicine*, 43:60-8.
3. Irmalita, Juzar DA, Andrianto, Setianto BY, Tobing DP, Firman D, et al. 2015. Pedoman Tatalaksana Sindrom Koroner Akut. Jakarta: PERKI.
4. Kumar A, Cannon CP. 2009. Acute Coronary Syndromes: Diagnosis and Management, Part I. *Mayo Clin Proc*, 84(10):917-38.
5. Mendis S. 2014. Global target 1: A 25% relative reduction in overall mortality from cardiovascular diseases, cancer, diabetes or chronic respiratory diseases. Dalam: Armstrong T (Editor), Global Status Report on Non Communicable Disease. Switzerland: WHO, p. 9-20.
6. Mihardja LK, Delima, Soetiarto F, Suhardi, Kristanto AY. 2013. Penyakit tidak menular. Dalam: Kementerian Kesehatan Republik Indonesia, penyunting. Riset Kesehatan Dasar. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian Republik Indonesia, p. 83-99.
7. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. 2009. Galectin-3: a novel mediator of heart failure development and progression. *European Journal of Heart Failure*, 11(9):811-7.
8. Salvagno GL, Pavan C. 2016. Prognostic biomarkers in acute coronary syndrome. *Ann Transl Med*, 4(13):258
9. de Boer RA, Yu L, van Veldhuisen DJ. 2010. Galectin-3 in Cardiac Remodeling and Heart Failure. *Curr Heart Fail Rep*, 7:1-8.
10. Santos-Gallego CG, Picatoste B, Badimon JJ. 2014. Pathophysiology of Acute Coronary Syndrome. *Curr Atheroscler Rep*, 16:401.
11. Crea F, Liuzzo G. 2013. Pathogenesis of Acute Coronary Syndromes. *J Am Coll Cardiol*, 61(1):1-11.

12. Kong P, Christia P, Frangogiannis NG. 2014. The pathogenesis of cardiac fibrosis. *Cell Mol Life Sci*, 71(4):549-74.
13. Talman V, Ruskoaho H. 2016. Cardiac fibrosis in myocardial infarction—from repair and remodeling to regeneration. *Cell Tissue Res*, 365(3):563-81.
14. Drake RL, Vogl AW, Mitchell AWM. 2015. Gray's Anatomy for Students, Third Edition. Philadelphia: Churchill Livingstone.
15. Kierszenbaum AL, Tres LL. 2016. Histology and Cell Biology: An Introduction to Pathology, Fourth Edition. Philadelphia: Elsevier Saunders.
16. Costanzo LS. 2014. Physiology, Fifth Edition. Philadelphia: Saunders.
17. Tortora GJ, Derrickson B. 2012. Principles of Anatomy and Physiology, Thirteenth Edition. Hoboken: John Wiley & Sons, Inc.
18. Thaler MS. 2013. Satu-satunya Buku EKG yang Anda Perlukan, Edisi 7. Jakarta: EGC.
19. Barrett KE, Barman SM, Boitano S, Brooks HL. 2012. Ganong's Review of Medical Physiology, Twenty-Fourth Edition. New York: McGraw-Hill.
20. Sherwood L. 2010. Human Physiology: From Cells to Systems, Seventh Edition. Belmont: Brooks/Cole.
21. Strom JB, Libby P. 2011. Atherosclerosis. Dalam: Lilly LS (Editor), Pathophysiology of Heart Disease: A Collaborative Project of Medical Students and Faculty, Fifth Edition. Philadelphia: Lippincott Williams & Wilkins.
22. Rhee JW, Sabatine MS, Lilly LS. 2011. Acute Coronary Syndromes. Dalam: Lilly LS (Editor), Pathophysiology of Heart Disease: A Collaborative Project of Medical Students and Faculty, Fifth Edition. Philadelphia: Lippincott Williams & Wilkins.
23. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J. 2010. Myocardial remodeling after infarction: the role of myofibroblasts. *Nat Rev Cardiol*, 7:30-7.
24. Duan J, Gherghe C, Liu D, Hamlett E, Srikantha L, Rodgers L, et al. 2012. Wnt1/bcatenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. *The EMBO Journal*, 31(2):429-42.

25. Lajiness JD, Conway SJ. 2013. Origin, development, and differentiation of cardiac fibroblasts. *J Mol Cell Cardiol*, 70:2-8.
26. Davis J, Molkenin JD. 2013. Myofibroblasts: Trust your heart and let fate decide. *J Mol Cell Cardiol*, 70:9-18.
27. Frangogiannis NG. 2014. The inflammatory response in myocardial injury, repair, and remodelling. *Nat Rev Cardiol*, 11:255-65.
28. Shinde AV, Frangogiannis NG. 2013. Fibroblasts in myocardial infarction: a role in inflammation and repair. *J Mol Cell Cardiol*, 70:74-82.
29. Yang RY, Rabinovich GA, Liu FT. 2008. Galectins: structure, function and therapeutic potential. *Expert Reviews in Molecular Medicine*, 10(17).
30. Eliaz I. 2013. The Role of Galectin-3 as a Marker of Cancer and Inflammation in a Stage IV Ovarian Cancer Patient with Underlying Pro-Inflammatory Comorbidities. *Case Rep Oncol*, 6:343-9.
31. Li LC, Li J, Gao J. 2014. Functions of Galectin-3 and Its Role in Fibrotic Diseases. *J Pharmacol Exp Ther*, 351:336-43.
32. Weir RAP, Petrie CJ, Murphy CA, Clements S, Steedman T, Miller AM, et al. 2013. Galectin-3 and Cardiac Function in Survivor of Acute Myocardial Infarction. *Circ Heart Fail*, 6:492-8.
33. Elabscience Biotechnology Inc. 2017. Human GAL3 (Galectin 3) ELISA Kit: Instruction manual, 7th edition. Houston, TX.
34. Ducharme A, Tardif JC. 2017. Echocardiography in Patients with Myocardial Infarction. Dalam Morrow D (Editor), *Myocardial Infarction: A Companion to Braunwald's Heart Disease*. St. Louis: Elsevier.
35. Tumbelaka AR, Riono P, Sastroasmoro S, Wirjodiarjo M, Pudjiastuti P, Firman K. 2011. Pemilihan Uji Hipotesis. Dalam: Sastroasmoro S, Ismael S (Editor), *Dasar-dasar Metodologi Penelitian Klinis Edisi ke-4*. Jakarta: Sagung Seto.
36. Tandon A, Villa CR, Hor KN, Jefferies JL, Gao Z, Towbin JA, et al. 2015. Myocardial Fibrosis Burden Predicts Left Ventricular Ejection Fraction and Is Associated With Age and Steroid Treatment Duration in Duchenne Muscular Dystrophy. *J Am Heart Assoc*, 4:e001338.
37. Milano AD, Faggian G, Dodonov M, Golia G, Tomezzoli A, Bortolotti U, et al. 2012. Prognostic value of myocardial fibrosis in patients with severe aortic valve stenosis. *J Thorac Cardiovasc Surg*, 144:830-7.

38. Nucifora G, Aquaro GD, Pingitore A, Masci PG, Lombardi M. 2011. Myocardial fibrosis in isolated left ventricular non-compaction and its relation to disease severity. *European Journal of Heart Failure*, 13:170-6.
39. Rodriguez-Reyna TS, Morelos-Guzman M, Hernandez-Reyes P, Montero-Duarte K, Martinez-Reyes C, Reyes-Utrera C, et al. 2015. Assessment of myocardial fibrosis and microvascular damage in systemic sclerosis by magnetic resonance imaging and coronary angiotomography. *Rheumatology*, 54:647-54.
40. van Heerebeek L, Hamdani N, Handoko L, Falcao-Pires I, Musters RJ, Kupreishvili K, et al. 2008. Diastolic Stiffness of the Failing Diabetic Heart. *Circulation*, 117:43-51.
41. Moreo A, Ambrosio G, De Chiara B, Pu M, Tran T, Mauri F, et al. 2009. Influence of Myocardial Fibrosis on Left Ventricular Diastolic: Non-Invasive Assessment by CMR and ECHO. *Circ Cardiovasc Imaging*, 2(6):437-43.
42. Cameli M, Mondillo S, Righini FM, Lisi M, Dokollari A, Lindqvist P, et al. 2016. Left Ventricular Deformation and Myocardial Fibrosis in Patients With Advanced Heart Failure Requiring Transplantation. *J Card Fail*, 22(11):901-7.
43. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. 2012. Galectin-3, A Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community. *J Am Coll Cardiol*, 60(14):1249-56.
44. Chen K, Jiang RJ, Wang CQ, Yin ZF, Fan YQ, Cao JT, et al. 2013. Predictive value of plasma galectin-3 in patients with chronic heart failure. *Eur Rev Med Pharmacol Sci*, 17:1005-11.
45. Yalcin MU, Gurses K, Kocyigit D, Canpinar H, Canpolat U, Evranos B, et al. 2015. The Association of Serum Galectin-3 Levels with Atrial Electrical and Structural Remodeling. *J Cardiovasc Electrophysiol*, 26(6):635-40.
46. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RRJ, Januzzi JL. 2010. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. *European Journal of Heart Failure*, 12:826-32.
47. Liu YH, D'Ambrosio M, Liao Td, Peng H, Rhaleb NE, Sharma U, et al. 2009. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. *Am J Physiol Heart Circ Physiol*, 296:H404-H412.

48. Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D'Angelo A, Schirinzi S, et al. 2011. Galectin-3 Plasma Levels and Coronary Artery Disease: A New Possible Biomarker of Acute Coronary Syndrome. *Int J Immunopathol Pharmacol*, 24(4):905-13.
49. Winter MP, Wiesbauer F, Alimohammadi A, Blessberger H, Pavo N, Schillinger M, et al. 2016. Soluble galectin-3 is associated with premature myocardial infarction. *Eur J Clin Invest*, 46(5):386-91.
50. Gucuk IE, Akin SS, Kafes H, Basyigit F, Karalok N, Guray Y, et al. 2016. Evaluation of galectin-3 levels in acute coronary syndrome. *Ann Cardiol Angeiol*, 65(1):26-30.
51. Singaas EG, Manhenke CA, Dickstein K, Orn S. 2016. Circulating Galectin-3 Levels Are Increased in Patients with Ischemic Heart Disease, but Are Not Influenced by Acute Myocardial Infarction. *Cardiology*, 134:398-405.
52. Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, et al. 2011. Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22. *Clinical Chemistry*, 58(1):267-73.

